Virtus Biotech Clinical Trials ETF
16 hedge funds and large institutions have $5.28M invested in Virtus Biotech Clinical Trials ETF in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
30.21% more ownership
Funds ownership: 0% → 30.21% (+30%)
23% more funds holding
Funds holding: 13 → 16 (+3)
2% less capital invested
Capital invested by funds: $5.39M → $5.28M (-$110K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$469K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$462K |
| 3 |
Goldman Sachs
New York
|
+$324K |
| 4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$138K |
| 5 |
SG Americas Securities
New York
|
+$72.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$569K |
| 2 |
Morgan Stanley
New York
|
-$49.3K |
| 3 |
LPL Financial
San Diego,
California
|
-$28.5K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
-$15K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$11K |
BBC Hedge Fund Activity: Q4 2016 in Review
16 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2016, worth a combined $5.28M — down 2% from $5.39M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BBC positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $469K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $569K sold.
- 16 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2016, up from 13 in Q3 2016.
- Funds reported $5.28M of Virtus Biotech Clinical Trials ETF stock for Q4 2016, down 2% quarter-over-quarter.
- 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2016 and 2 closed out, a net change of +4 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2016 was Royal Bank of Canada, an estimated $469K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2016 was Susquehanna International Group, an estimated $569K sold.
Based on aggregated 13F filings for Q4 2016.